OrganOx has completed a $142m primary and secondary equity financing to accelerate the rollout of its metra devices.
The oversubscribed round was led by external investor HealthQuest, alongside new investors Sofina, Soleus Capital, and Avidity Partners and with support from existing investors BGF and Lauxera Capital Partners.
Leading medical journal, The Lancet, has published the findings of the 40,000 patient ORFAN study demonstrating the ability of Caristo’s CaRi-Heart FAI-Score to predict fatal and non-fatal cardiac events.
Caristo’s AI-Risk model, CaRi-Heart Risk Score, outperformed other scores in routine clinical use for prediction of cardiac mortality, and when presented to clinicians, resulted in changes of management decision in 45% of the patients.
Biofidelity has raised an internally led $24m funding round with support from existing investors including Agilent Technologies, Octopus Ventures, BlueYard Capital, and Longwall Ventures.
The funding will support commerical rollout following the launch of its first product ASPYRE-Lung, a novel test that simplifies and accelerates the detection of biomarkers for non-small cell lung cancer.
OQC has announced its ongoing $100m Series B, led by Japanese venture capital fund SBI Investment, in addition to existing investors Oxford Science Enterprises (OSE), University of Tokyo Edge Capital Partners (UTEC), and Lansdowne Partners.
The announcement is made alongside the launch of OQC Toshiko the Company’s powerful next generation 32-qubit platform, deployed to commercial data-centres, enabling businesses to tap into ground-breaking technology from anywhere in the world, seamlessly and securely.
OrganOx has raised £25m to continue the development and commercial rollout of metra, its fully automated normothermic perfusion (NMP) device for liver transplantation.
The round was led by external investor Lauxera Capital Partners, with support from existing investors.
